AU2001247968A1 - Use of asiatic acid or asiaticoside for treatment of cancer - Google Patents

Use of asiatic acid or asiaticoside for treatment of cancer

Info

Publication number
AU2001247968A1
AU2001247968A1 AU2001247968A AU4796801A AU2001247968A1 AU 2001247968 A1 AU2001247968 A1 AU 2001247968A1 AU 2001247968 A AU2001247968 A AU 2001247968A AU 4796801 A AU4796801 A AU 4796801A AU 2001247968 A1 AU2001247968 A1 AU 2001247968A1
Authority
AU
Australia
Prior art keywords
asiaticoside
cancer
treatment
asiatic acid
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001247968A
Other languages
English (en)
Inventor
Azizol Abdul Kadir
Lean Teik Ng
Se-Kyung Oh
Chokyun Rha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of Malaysia
Massachusetts Institute of Technology
Original Assignee
Government of Malaysia
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of Malaysia, Massachusetts Institute of Technology filed Critical Government of Malaysia
Publication of AU2001247968A1 publication Critical patent/AU2001247968A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001247968A 2000-08-29 2001-02-14 Use of asiatic acid or asiaticoside for treatment of cancer Abandoned AU2001247968A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
MYPI20003987A MY138883A (en) 2000-08-29 2000-08-29 Use of asiatic acid for treatment of cencer
MYPI20003987 2000-08-29
PCT/US2001/040103 WO2002017904A1 (en) 2000-08-29 2001-02-14 Use of asiatic acid or asiaticoside for treatment of cancer

Publications (1)

Publication Number Publication Date
AU2001247968A1 true AU2001247968A1 (en) 2002-03-13

Family

ID=19749475

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001247968A Abandoned AU2001247968A1 (en) 2000-08-29 2001-02-14 Use of asiatic acid or asiaticoside for treatment of cancer

Country Status (9)

Country Link
US (1) US20040097463A1 (cg-RX-API-DMAC10.html)
EP (1) EP1313462B1 (cg-RX-API-DMAC10.html)
JP (2) JP2004507496A (cg-RX-API-DMAC10.html)
AT (1) ATE415962T1 (cg-RX-API-DMAC10.html)
AU (1) AU2001247968A1 (cg-RX-API-DMAC10.html)
DE (1) DE60136826D1 (cg-RX-API-DMAC10.html)
DK (1) DK1313462T3 (cg-RX-API-DMAC10.html)
MY (1) MY138883A (cg-RX-API-DMAC10.html)
WO (1) WO2002017904A1 (cg-RX-API-DMAC10.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144312A1 (en) * 2001-10-30 2003-07-31 Schoenhard Grant L. Inhibitors of ABC drug transporters in multidrug resistant cancer cells
KR100571886B1 (ko) 2004-02-23 2006-04-17 학교법인 영남학원 아시아틱산을 포함하는 피부암 예방 또는 치료용 조성물
WO2005082415A2 (en) * 2004-02-25 2005-09-09 Dana Farber Cancer Institute, Inc. Inhibitors of insulin-like growth factor receptor-1 for inhibiting tumor cell growth
WO2006012015A2 (en) * 2004-06-29 2006-02-02 Oregon Health And Science University Methods and compositions for nerve regeneration
US20070010459A1 (en) * 2005-01-14 2007-01-11 Ying Liu Application of asiatic acid and its derivatives to treat pulmonary fibrosis
WO2006081371A2 (en) * 2005-01-27 2006-08-03 Research Development Foundation Combination therapy with triterpenoid compounds and proteasome inhibitors
US8742167B2 (en) 2008-01-11 2014-06-03 Shanghai Institute Of Pharmaceutical Industry Therapeutic formulations based on asiatic acid and selected salts thereof
EP3062106B1 (en) 2008-04-16 2020-11-11 The Johns Hopkins University Method for determining androgen receptor variants in prostate cancer
WO2009148623A2 (en) 2008-06-05 2009-12-10 Stc.Unm Methods and related compositions for the treatment of cancer
US9108372B2 (en) 2009-12-21 2015-08-18 Pirelli Tyre S.P.A. Process and plant for building tyres
CA2802154C (en) 2010-06-10 2017-02-28 Indus Biotech Private Limited A method for preparation of highly pure asiaticoside composition from centella asiatica and a method of use thereof
ES2694582T3 (es) * 2011-01-31 2018-12-21 Lucolas-M.D. Ltd. Combinaciones de inhibidores de aromatasa y antioxidantes
US20140194368A1 (en) * 2013-01-04 2014-07-10 Beech Tree Labs, Inc. Method of Treating Cancer by Administration of Low Levels of Heat Shock Protein 70 (HSP70)
CA2904170A1 (en) 2013-03-14 2014-09-25 University Of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
CN105307641A (zh) * 2013-05-03 2016-02-03 西莱克塔生物科技公司 用于降低不期望体液免疫应答的给药组合
KR20160058774A (ko) 2013-08-12 2016-05-25 토카이 파마슈티컬, 아이엔씨. 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
WO2015179404A1 (en) 2014-05-19 2015-11-26 The Johns Hopkins University Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer
WO2016033114A1 (en) * 2014-08-25 2016-03-03 The Johns Hopkins University Methods and compositions related to prostate cancer therapeutics
EP3124047A1 (en) * 2015-07-28 2017-02-01 Merz Pharma GmbH & Co. KGaA Pentacyclic triterpenoids for injection lipolysis
CN108057034A (zh) * 2016-11-09 2018-05-22 香港中文大学 柚皮素和积雪草酸组合治疗癌症
EP4599848A3 (en) 2017-03-11 2025-12-03 Cartesian Therapeutics, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
WO2019200585A1 (en) * 2018-04-19 2019-10-24 The Chinese University Of Hong Kong Naringenin and asiatic acid combination treatment of cancers
US20210380685A1 (en) * 2018-10-18 2021-12-09 Sinomab Bioscience Limited Methods of Treating Rheumatoid Arthritis
CN109528735B (zh) * 2019-01-30 2021-03-12 中国药科大学 积雪草苷在制备治疗皮肤癌药物中的新用途
US12553041B2 (en) 2019-06-04 2026-02-17 Cartesian Therapeutics Inc. Formulations and doses of pegylated uricase
CN110200981A (zh) * 2019-06-06 2019-09-06 中国药科大学 五环三萜皂苷的医药用途及其药物组合物
US20240034788A1 (en) * 2020-08-20 2024-02-01 The Board Of Trustees Of The Leland Stanford Junior University Abscopal therapy for cancer
US20250275978A1 (en) * 2024-03-04 2025-09-04 Cardiff Oncology, Inc. Use of onvansertib as monotherapy and in combination with cetuximab in treating ras wild-type colorectal cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB923414A (en) * 1960-04-13 1963-04-10 Laroche Navarron Lab Therapeutic compositions comprising asiatic and arjunolic acids
IT1203515B (it) * 1987-02-26 1989-02-15 Indena Spa Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono
EP0383171A3 (en) * 1989-02-11 1991-07-24 Hoechst Aktiengesellschaft 2,3,23-trihydroxy-urs-12-ene derivatives for treating cognitive disorders
FR2714598B1 (fr) * 1993-12-30 1996-02-09 Oreal Composition amincissante à deux types de liposomes pour traitement topique, son utilisation.
JPH08133952A (ja) * 1994-11-07 1996-05-28 Shiseido Co Ltd 皮膚外用剤
EP0944571B1 (en) * 1996-11-27 2001-06-13 Dong Kook Pharmaceutical Co., Ltd. Asiatic acid derivatives having modified a-ring
IT1288257B1 (it) * 1996-11-29 1998-09-11 Paoli Ambrosi Gianfranco De Composizione per uso cosmetico,farmaceutico o dietetico a base di un aminozucchero e/o di un acido poliidrossilico
FR2763336B1 (fr) * 1997-05-14 1999-08-06 Lvmh Rech Esters de tocopherol et leurs utilisations en cosmetique et pharmacie
AU2005251463A1 (en) * 2004-06-14 2005-12-22 Zoser B. Salama Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody

Also Published As

Publication number Publication date
JP2012092110A (ja) 2012-05-17
DK1313462T3 (da) 2009-03-30
DE60136826D1 (de) 2009-01-15
MY138883A (en) 2009-08-28
JP2004507496A (ja) 2004-03-11
WO2002017904A1 (en) 2002-03-07
ATE415962T1 (de) 2008-12-15
EP1313462B1 (en) 2008-12-03
JP5421340B2 (ja) 2014-02-19
EP1313462A1 (en) 2003-05-28
US20040097463A1 (en) 2004-05-20

Similar Documents

Publication Publication Date Title
MY138883A (en) Use of asiatic acid for treatment of cencer
WO2003080582A3 (de) Fredericamycin-derivate
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
AU7031500A (en) Therapeutic quinazoline compounds
WO2004006858A3 (en) Compounds, compositions, and methods employing same
FI956014A0 (fi) Nona- ja dekapeptidien käyttö lääkkeen valmistamiseksi AIDS-sairauden hoitoon
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
AU2386201A (en) Substituted sapogenins and their use
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
WO2000066528A3 (en) Quinones for treatment of diseases
WO2001079164A3 (en) N-substituted dithiocarbamates for the treatment of biological disorders
AU2158601A (en) Antiviral agent for use in treatment of cancer
AU7313896A (en) Pharmaceutical composition containing an activin or inhibin stimulator
GB9907571D0 (en) Compounds
WO1999051256A3 (en) Use of l-glu-l-trp in the treatment of hiv infection
AU3919001A (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
AU2001267561A1 (en) Combination preparations of 3-n-formylhydroxylaminopropyl phosphonic acid derivatives or 3-n-acetylhydroxylaminopropyl phosphonic acid derivatives combined withspecific pharmaceutical active agents
WO2002066492A3 (fr) Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques.
WO2000069841A3 (en) Benzofuranylaminoalcohols
PL367401A1 (en) Utilization of buprenorphine in urinary incontinence therapy
WO2000048584A3 (en) Aroyl aminoacyl pyrroles for use in the treatment of neuropathic pain
PL355113A1 (en) Novel fusidic acid derivatives
AU2001256440A1 (en) Medicines for treating tumoral pathologies containing the ro5-4864 compound and an apoptosis-inducing agent
AU6290398A (en) Inclusion complexes in aqueous solution
AU2002241416A1 (en) Dermatological agent for the treatment of skin trauma, especially in burn conditions